188 related articles for article (PubMed ID: 34598060)
21. A novel nucleolin-binding peptide for Cancer Theranostics.
Kim JH; Bae C; Kim MJ; Song IH; Ryu JH; Choi JH; Lee CJ; Nam JS; Kim JI
Theranostics; 2020; 10(20):9153-9171. PubMed ID: 32802184
[No Abstract] [Full Text] [Related]
22. Ultrasound activated nanosensitizers for sonodynamic therapy and theranostics.
Li L; Lin H; Li D; Zeng Y; Liu G
Biomed Mater; 2021 Feb; 16(2):022008. PubMed ID: 33316792
[TBL] [Abstract][Full Text] [Related]
23. Applications of Two-Dimensional Nanomaterials in Breast Cancer Theranostics.
Mohammadpour Z; Majidzadeh-A K
ACS Biomater Sci Eng; 2020 Apr; 6(4):1852-1873. PubMed ID: 33455353
[TBL] [Abstract][Full Text] [Related]
24. Aptamers and their applications in nanomedicine.
Sun H; Zu Y
Small; 2015 May; 11(20):2352-64. PubMed ID: 25677591
[TBL] [Abstract][Full Text] [Related]
25. Nanotechnology and nanomedicine: going small means aiming big.
Teli MK; Mutalik S; Rajanikant GK
Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
[TBL] [Abstract][Full Text] [Related]
26. Emerging theranostics to combat cancer: a perspective on metal-based nanomaterials.
Agnihotri TG; Gomte SS; Jain A
Drug Dev Ind Pharm; 2022 Nov; 48(11):585-601. PubMed ID: 36448770
[TBL] [Abstract][Full Text] [Related]
27. Theranostics for Breast Cancer Stem Cells.
Moon WK; Kim HS
Adv Exp Med Biol; 2021; 1187():267-281. PubMed ID: 33983583
[TBL] [Abstract][Full Text] [Related]
28. Emerging trends in aggregation induced emissive luminogens as bacterial theranostics.
Kumari R; Sunil D
J Drug Target; 2021 Sep; 29(8):793-807. PubMed ID: 33583291
[TBL] [Abstract][Full Text] [Related]
29. Responsible healthcare innovation: anticipatory governance of nanodiagnostics for theranostics medicine.
Fisher E; Boenink M; van der Burg S; Woodbury N
Expert Rev Mol Diagn; 2012 Nov; 12(8):857-70. PubMed ID: 23249203
[TBL] [Abstract][Full Text] [Related]
30. Combining Antimicrobial Peptides with Nanotechnology: An Emerging Field in Theranostics.
Mohid SA; Bhunia A
Curr Protein Pept Sci; 2020; 21(4):413-428. PubMed ID: 31889488
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional nanoparticles for drug delivery and molecular imaging.
Bao G; Mitragotri S; Tong S
Annu Rev Biomed Eng; 2013; 15():253-82. PubMed ID: 23642243
[TBL] [Abstract][Full Text] [Related]
32. The use of aptamers in prostate cancer: A systematic review of theranostic applications.
Campos-Fernández E; Oliveira Alqualo N; Moura Garcia LC; Coutinho Horácio Alves C; Ferreira Arantes Vieira TD; Caixeta Moreira D; Alonso-Goulart V
Clin Biochem; 2021 Jul; 93():9-25. PubMed ID: 33794195
[TBL] [Abstract][Full Text] [Related]
33. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
34. New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms.
Falagan-Lotsch P; Grzincic EM; Murphy CJ
Bioconjug Chem; 2017 Jan; 28(1):135-152. PubMed ID: 27973767
[TBL] [Abstract][Full Text] [Related]
35. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
36. Nanomedicine-based strategies to target and modulate the tumor microenvironment.
Mendes BB; Sousa DP; Conniot J; Conde J
Trends Cancer; 2021 Sep; 7(9):847-862. PubMed ID: 34090865
[TBL] [Abstract][Full Text] [Related]
37. The advanced role of carbon quantum dots in nanomedical applications.
Devi P; Saini S; Kim KH
Biosens Bioelectron; 2019 Sep; 141():111158. PubMed ID: 31323605
[TBL] [Abstract][Full Text] [Related]
38. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders.
Hassanzadeh P; Atyabi F; Dinarvand R
Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367
[TBL] [Abstract][Full Text] [Related]
39. Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q; De Vlaeminck Y; Hanssens H; D'Huyvetter M; Raes G; Goyvaerts C; Keyaerts M; Devoogdt N; Breckpot K
Theranostics; 2019; 9(25):7772-7791. PubMed ID: 31695800
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA Theranostics in Prostate Cancer Precision Medicine.
Matin F; Jeet V; Clements JA; Yousef GM; Batra J
Clin Chem; 2016 Oct; 62(10):1318-33. PubMed ID: 27540032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
